Browse the evidence

Seasonal gene expression patterns in the immune system are inverted between the Northern and Southern hemispheres, indicating a photoperiod-driven circannual rhythm.

If you move from the Northern to the Southern hemisphere (or vice versa), your immune system's seasonal gene expression will invert to match the new local season, suggesting your body tracks daylight length to regulate immunity.

Roux-en-Y gastric bypass (RYGB) surgery improves glucose homeostasis and reduces appetite largely through altered gut hormonal milieus (increased GLP-1/PYY, decreased ghrelin) rather than solely through caloric restriction or malabsorption.

Bariatric surgery like RYGB works not just by making your stomach smaller, but by changing the hormones your gut releases, which helps fix diabetes and reduces hunger signals to your brain.

In human abdominal (visceral) obesity, circulating levels of the endocannabinoid 2-AG are significantly elevated and correlate with visceral fat mass, serving as a critical correlate of peripheral endocannabinoid system dysregulation.

If you have abdominal obesity, your body likely has higher levels of 2-AG, a lipid messenger that promotes fat storage and insulin resistance. This is not just 'being overweight'; it is a specific hormonal state driven by visceral fat. Addressing visceral fat accumulation is key to correcting this dysregulation.

In visceral adipose tissue of obese individuals, the expression of the CB1 receptor and the degrading enzyme FAAH is downregulated, creating a negative-feedback loop that sustains high local endocannabinoid activity.

Your visceral fat tissue actively downregulates the enzymes that break down fat-storing signals (like FAAH) and receptors (CB1). This creates a self-reinforcing cycle where high fat levels lead to hormonal changes that promote further fat storage. Breaking this cycle requires addressing the visceral fat itself.

Elevated circulating 2-AG levels in visceral obesity are negatively correlated with insulin sensitivity, as measured by glucose infusion rate during euglycemic-hyperinsulinemic clamp, independent of total body fat mass.

High levels of 2-AG in your blood are linked to insulin resistance, meaning your body struggles to use insulin effectively to manage blood sugar. This link exists even when you account for how much fat you have, suggesting 2-AG plays a direct role in metabolic dysfunction.

Growth hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) supplementation improves cardiovascular health by attenuating mitochondrial oxidative stress, upregulating antioxidant enzymes, and preserving endothelial progenitor cell function.

Maintaining healthy levels of Growth Hormone and IGF-1 is critical for heart health in aging. Deficiency in these hormones is linked to premature atherosclerosis and higher cardiovascular mortality. While extremely high levels may have other risks, low-normal levels are associated with increased heart disease risk, suggesting that preserving this hormonal axis is beneficial for vascular longevity.

High-intensity interval exercise increases cerebral angiogenesis and VEGFA levels via the lactate receptor HCAR1, a mechanism absent in skeletal muscle.

To maximize brain blood vessel growth, you likely need to exercise at high intensities that elevate blood lactate levels, as this triggers a specific receptor (HCAR1) that low-intensity exercise may not sufficiently activate.

BMAL1 is a necessary transcription factor for adipogenesis; its absence prevents lipid accumulation and expression of key adipocyte genes (PPARγ2, aP2), while its restoration or overexpression promotes lipogenesis and lipid synthesis.

This research highlights that your body's internal clock (circadian rhythm) and genetic factors play a crucial role in how fat cells develop and store energy. While you cannot change your genes, maintaining a regular sleep schedule and avoiding late-night eating might support healthy fat metabolism by aligning with your body's natural BMAL1 rhythms.

Rosiglitazone reduces liver fat content and increases insulin clearance in patients with type 2 diabetes, whereas metformin improves hepatic insulin sensitivity without altering liver fat.

For patients with type 2 diabetes, rosiglitazone (a PPAR-gamma agonist) significantly reduces liver fat and improves how the liver clears insulin, leading to better peripheral glucose uptake. Metformin, while effective for lowering blood sugar and improving hepatic insulin sensitivity, does not reduce liver fat. This suggests that the choice of medication may depend on whether reducing liver fat is a primary therapeutic goal.

Rosiglitazone increases insulin clearance in patients with type 2 diabetes, which contributes to the decrease in fasting serum insulin concentrations.

Rosiglitazone helps the liver clear insulin more efficiently, which lowers fasting insulin levels. This is linked to the drug's ability to reduce liver fat and increase adiponectin. Metformin does not have this effect on insulin clearance.

Rosiglitazone increases serum adiponectin concentrations and adipose tissue gene expression of PPAR-gamma, adiponectin, and lipoprotein lipase, whereas metformin does not.

Rosiglitazone significantly boosts adiponectin, a hormone that improves insulin sensitivity and reduces liver fat. Metformin does not have this effect on adiponectin levels.

Excess weight gain causes hypertension primarily through activation of the sympathetic nervous system (SNS), mediated by leptin and melanocortin receptors, leading to increased renal sodium reabsorption and impaired pressure natriuresis.

If you are obese, your high blood pressure is likely driven by your nervous system being overactive due to hormonal signals from fat cells. Losing weight helps, but understanding that your body's 'thermostat' for blood pressure is set too high by these signals is key. Treatments that block these signals (like certain blood pressure meds) are often more effective in obese individuals.

Obesity induces 'selective leptin resistance' where the appetite-suppressing effects of leptin are blunted, but the blood pressure-raising effects (via SNS activation) remain intact.

Your body produces high levels of leptin, but your brain ignores its 'stop eating' command. However, it still listens to leptin's command to raise blood pressure. This mismatch makes losing weight and controlling blood pressure harder. Treatments that mimic or bypass leptin signaling (like GLP-1 agonists) may help by addressing these pathways.

Activation of the central melanocortin 4 receptor (MC4R) is necessary for obesity to increase sympathetic nervous system activity and arterial pressure.

Blocking the MC4 receptor lowers blood pressure in obese individuals, even if they gain weight. This suggests that targeting this specific brain pathway is a viable strategy for treating obesity-related hypertension.

Chronic systemic inflammation impairs muscle homeostasis and myogenesis by activating catabolic pathways (proteasome/autophagy) and inhibiting anabolic signaling (IGF-1/Akt/mTOR), leading to muscle atrophy.

If you are dealing with a chronic inflammatory condition, muscle loss is driven by biological signals (cytokines) that break down muscle and block growth. Standard advice might focus only on eating more protein, but addressing the underlying inflammation (through medical treatment or specific lifestyle interventions like exercise which can correct cytokine levels) is crucial to preserving muscle mass.

Chronic inflammation impairs muscle regeneration by disrupting the transition of satellite cells from proliferation to differentiation, often leading to fibrosis and reduced muscle quality.

When you injure your muscle, some inflammation is necessary for it to heal properly. Chronic, long-term inflammation (from disease or overuse) is what stops repair and causes scarring. Focus on treating the underlying chronic condition rather than just masking acute pain with anti-inflammatories, as the body needs the initial inflammatory signal to start regeneration.

Berberine activates AMPK and improves insulin sensitivity by inhibiting mitochondrial respiratory complex I, a mechanism shared with metformin and rosiglitazone.

Berberine improves insulin sensitivity by inhibiting mitochondrial complex I, similar to prescription drugs like metformin. However, standard berberine has very poor oral bioavailability, requiring high doses in animal models. A derivative, dihydroberberine, shows significantly improved efficacy and absorption in rodents, suggesting that formulation matters for clinical utility.

Selenium is preferentially retained and redistributed to endocrine tissues (thyroid, adrenals, pituitary, testes, ovary) and the brain during nutritional depletion, prioritizing thyroid hormone homeostasis and cellular defense over other organs.

Ensure adequate dietary selenium intake to support thyroid and endocrine health. The body prioritizes these organs, so maintaining sufficient levels helps protect thyroid function and hormone regulation, especially if you live in a region with low soil selenium.

Selenium status modulates the expression and activity of selenoproteins that regulate transcription by redox-sensitive nuclear hormone receptors, linking selenium metabolism to broader endocrine signaling.

Maintain adequate selenium levels to support the body's redox balance, which influences how hormones interact with cells and regulate gene expression.

Excessive lipolysis from visceral adipose tissue drives lipotoxicity and insulin resistance by flooding the liver with free fatty acids, leading to ectopic fat accumulation and metabolic dysfunction.

Focus on improving insulin sensitivity rather than just cutting dietary fat. Visceral fat is metabolically active and releases fatty acids that clog up your liver and muscles, causing insulin resistance. Reducing visceral fat through exercise and metabolic health improvements can lower this harmful fatty acid overflow.

Visceral adipose tissue is more lipolytically active than subcutaneous fat, releasing fatty acids directly into the portal vein to the liver, thereby driving hepatic steatosis and insulin resistance more strongly than subcutaneous fat.

Waist circumference is a better health indicator than total weight. Reducing visceral fat through aerobic exercise and metabolic health improvements is crucial for preventing liver disease and type 2 diabetes, even if your total weight doesn't change drastically.

Estrogen deficiency during menopause leads to dysregulated lipid metabolism, characterized by increased LDL-C, increased triglycerides, and altered HDL subfractions, thereby increasing cardiovascular disease risk.

Understand that the drop in estrogen after menopause naturally raises your LDL cholesterol and triglycerides while lowering protective HDL. This increases your risk of heart disease. Managing this through diet (healthy fats, fiber) and potentially medical intervention is crucial for long-term heart health.

Obesity causes hypertension and chronic kidney disease through multiple mechanisms including increased renal tubular sodium reabsorption, sympathetic nervous system activation, RAAS activation, and physical compression of the kidneys by visceral fat.

Obesity is a direct cause of high blood pressure and kidney disease through specific physiological pathways like increased sodium retention and nerve system activation. Managing visceral fat is crucial for mitigating these risks.

RAAS blockade with ACE inhibitors or ARBs reduces proteinuria and slows the progression to end-stage renal disease in obese patients with proteinuria.

Obese patients with proteinuria benefit significantly from ACE inhibitors like ramipril, which can greatly reduce the risk of kidney failure.